Health
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study PopulationPURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Confe
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population","length":100,"tagName":"p"},{"type":"text","content":"PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference taking place April 1-5, 2025 in Vienna, Austria.","length":466,"tagName":"p"},{"type":"text","content":"In her presentation, Mary Hamby, Ph.D., VP of research at Cognition, compared changes in key proteins, called biomarkers, in the entire study population with changes observed in participants who began the study with lower levels of a protein called p-Tau217 in their blood. This protein, which can be measured with a blood test, has emerged as an indicator of Alzheimer’s disease pathology. Analysis of this low-p-Tau217 subgroup was defined in the SHINE study design in order to examine the impact of zervimesine in people with less neurodegeneration.","length":552,"tagName":"p"},{"type":"text","content":"In the overall study population, compared to participants treated with placebo, those who received zervimesine for six months had reductions in plasma biomarkers associated with Alzheimer’s disease processes. Further analysis showed that the SHINE low-p-Tau217 subgroup experienced a pronounced reduction in these key plasma biomarkers compared to placebo.","length":356,"tagName":"p"},{"type":"text","content":"Most notably, significant reductions were observed in the level of glial fibrillary acidic protein (GFAP), a protein associate...